Danaher to Acquire Masimo for $9.9 Billion, Bolstering Diagnostics Portfolio
Event summary
- Danaher will acquire Masimo for $9.9 billion, including debt, at $180 per share in cash.
- The deal is valued at approximately 18x Masimo's estimated 2027 EBITDA, or 15x with synergies.
- Masimo will operate as a standalone company within Danaher's Diagnostics segment.
- Danaher expects $125 million in annual cost synergies and $50 million in revenue synergies by the fifth year.
- The transaction is expected to close in the second half of 2026, subject to regulatory and shareholder approval.
The big picture
Danaher's acquisition of Masimo underscores a broader trend of consolidation in the diagnostics sector, as companies seek to enhance their capabilities in patient monitoring and acute care settings. The deal highlights Danaher's strategy to leverage its global scale and the Danaher Business System to drive innovation and improve patient outcomes. With this acquisition, Danaher aims to strengthen its position in the diagnostics market, competing with other major players in the space.
What we're watching
- Integration Challenges
- How Danaher will integrate Masimo's advanced sensor technology and AI-enabled monitoring into its existing diagnostics portfolio.
- Regulatory Hurdles
- Whether the transaction will face significant regulatory scrutiny given its size and the nature of the businesses involved.
- Growth Acceleration
- The pace at which Masimo's high-single digit core revenue growth will accelerate Danaher's Diagnostics segment.
Related topics